Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Autolus Therapeutics Ltd - ADR    AUTL

AUTOLUS THERAPEUTICS LTD - ADR

(AUTL)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/09/2019 07/10/2019 07/11/2019 07/12/2019 07/15/2019 Date
16.72(c) 16.09(c) 15.98(c) 16.01(c) 16.1(c) Last
428 555 309 079 69 661 66 212 51 929 Volume
+3.98% -3.77% -0.68% +0.19% +0.56% Change
More quotes
Financials (USD)
Sales 2019 3,73 M
EBIT 2019 -138 M
Net income 2019 -129 M
Debt 2019 -
Yield 2019 -
Sales 2020 2,35 M
EBIT 2020 -165 M
Net income 2020 -157 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -5,48x
P/E ratio 2020 -5,03x
Capi. / Sales2019 194x
Capi. / Sales2020 308x
Capitalization 724 M
More Financials
Company
Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products... 
More about the company
Latest news on AUTOLUS THERAPEUTICS LTD -
05/28Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
GL
05/15AUTOLUS THERAPEUTICS : Reports First Quarter 2019 Financial Results and Operatio..
AQ
05/14AUTOLUS THERAPEUTICS : Reports First Quarter 2019 Financial Results and Operatio..
AQ
05/07Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host ..
GL
04/27AUTOLUS THERAPEUTICS : FDA gives orphan drug status to AUTO3 for ALL
AQ
04/26AUTOLUS THERAPEUTICS : FDA orphan drug designation granted for Autolus acute lym..
AQ
04/25AUTOLUS THERAPEUTICS : Receives FDA Orphan Drug Designation for AUTO3 for Treatm..
AQ
04/23Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treat..
GL
04/17ARIX BIOSCIENCE : Autolus announces closing of public offering
AQ
04/16AUTOLUS THERAPEUTICS : Announces Pricing of Public Offering
AQ
More news
Sector news : Bio Therapeutic Drugs
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15The Galapagos drugs pipeline that has drawn in Gilead
RE
07/15Galapagos Shares Rise After $5.1 Billion Gilead Partnership Announced
DJ
More sector news : Bio Therapeutic Drugs
Chart AUTOLUS THERAPEUTICS LTD - ADR
Duration : Period :
Autolus Therapeutics Ltd - ADR Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUTOLUS THERAPEUTICS LTD -
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 44,0  $
Last Close Price 16,1  $
Spread / Highest target 211%
Spread / Average Target 173%
Spread / Lowest Target 136%
EPS Revisions
Managers
NameTitle
Christian Martin Itin Chairman & Chief Executive Officer
Christopher Vann Chief Operating Officer & Senior Vice President
Andrew J. Oakley Chief Financial Officer & Senior Vice President
Martin Pulé Chief Scientific Officer & Senior Vice President
Vijay Reddy Peddareddigari Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AUTOLUS THERAPEUTICS LTD - ADR-50.97%719
GILEAD SCIENCES8.82%84 164
VERTEX PHARMACEUTICALS6.43%45 080
REGENERON PHARMACEUTICALS-20.16%31 857
SAREPTA THERAPEUTICS INC43.04%11 437
GENMAB9.70%11 148